Caribou Biosciences (CRBU) News Today $1.96 -0.03 (-1.51%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Caribou Biosciences to Participate in Upcoming Investor ConferencesNovember 20 at 4:00 PM | globenewswire.comCaribou Biosciences (NASDAQ:CRBU) Earns "Buy" Rating from HC WainwrightNovember 19 at 3:47 AM | americanbankingnews.comThe Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc. – CRBUNovember 18 at 8:00 AM | globenewswire.comBuy Rating for Caribou Biosciences Backed by Strong Financial Position and Strategic Growth CatalystsNovember 15, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Caribou Biosciences (NASDAQ:CRBU)HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Friday.November 15, 2024 | marketbeat.comCRBU FY2024 EPS Raised by Brookline Capital ManagementNovember 13, 2024 | americanbankingnews.comFY2024 Earnings Forecast for CRBU Issued By Leerink PartnrsNovember 12, 2024 | americanbankingnews.comBrokers Set Expectations for CRBU FY2024 EarningsCaribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Stock analysts at Brookline Capital Management upped their FY2024 earnings estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, November 6th. Brookline Capital Management analyst L. Cann now expectNovember 11, 2024 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for CRBU EarningsCaribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Investment analysts at Leerink Partnrs raised their FY2024 earnings estimates for Caribou Biosciences in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now expects that the company will poNovember 11, 2024 | marketbeat.comSutro Biopharma (NASDAQ:STRO) versus Caribou Biosciences (NASDAQ:CRBU) Head-To-Head ReviewNovember 11, 2024 | americanbankingnews.comCaribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearNovember 10, 2024 | finance.yahoo.comCaribou Biosciences (NASDAQ:CRBU) Issues Quarterly Earnings ResultsCaribou Biosciences (NASDAQ:CRBU - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. The company had revenue of $2.02 million for the quarter, compared to analysts' expectations of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 43.47%.November 9, 2024 | marketbeat.comEvercore ISI Remains a Hold on Caribou Biosciences (CRBU)November 8, 2024 | markets.businessinsider.comCaribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comDimensional Fund Advisors LP Boosts Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU)Dimensional Fund Advisors LP lifted its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 25.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,623,283 shares of the company's stockOctober 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Sells 1,241,478 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)Point72 Asset Management L.P. decreased its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 34.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,343,540 shares of the company's stock after selling 1,241,478 shares durinOctober 3, 2024 | marketbeat.com1,482,900 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Bought by Renaissance Technologies LLCRenaissance Technologies LLC bought a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,482,900 shares of the company's stock, valued at approximatOctober 2, 2024 | marketbeat.comCaribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024September 25, 2024 | markets.businessinsider.comWith 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backingSeptember 18, 2024 | finance.yahoo.comCandriam S.C.A. Sells 520,000 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)Candriam S.C.A. lowered its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 45.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 625,063 shares of the company's stock after selling 520,000 sharSeptember 11, 2024 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Caribou Biosciences (CRBU)September 5, 2024 | markets.businessinsider.comCaribou Biosciences: FDA Grants Fast Track Designations To CB-010, CB-012September 4, 2024 | markets.businessinsider.comCaribou Biosciences (NASDAQ:CRBU) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Caribou Biosciences in a report on Tuesday.September 3, 2024 | marketbeat.comCaribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest UpdateCaribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the recipient of a significant decline in short interest in August. As of August 15th, there was short interest totalling 11,520,000 shares, a decline of 7.3% from the July 31st total of 12,430,000 shares. Approximately 14.4% of the company's stock are short sold. Based on an average daily volume of 2,170,000 shares, the short-interest ratio is currently 5.3 days.September 2, 2024 | marketbeat.comCaribou Biosciences to Participate in Upcoming Investor ConferencesAugust 26, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUAugust 17, 2024 | prnewswire.comCaribou Biosciences, Inc. to Post Q3 2024 Earnings of ($0.44) Per Share, HC Wainwright Forecasts (NASDAQ:CRBU)Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Investment analysts at HC Wainwright increased their Q3 2024 EPS estimates for shares of Caribou Biosciences in a report issued on Wednesday, August 14th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.44) perAugust 16, 2024 | marketbeat.comCaribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical OfficerAugust 12, 2024 | globenewswire.comBank of America Securities Keeps Their Buy Rating on Caribou Biosciences (CRBU)August 9, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUAugust 9, 2024 | prnewswire.comCaribou Biosciences (NASDAQ:CRBU) Announces Earnings ResultsCaribou Biosciences (NASDAQ:CRBU - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04. The company had revenue of $3.46 million during the quarter, compared to analysts' expectations of $3.31 million. Caribou Biosciences had a negative net margin of 345.05% and a negative return on equity of 33.42%.August 7, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Stock Rating Reaffirmed by Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and issued a $14.00 target price on shares of Caribou Biosciences in a report on Wednesday.August 7, 2024 | marketbeat.comCaribou Bioscience GAAP EPS of -$0.42 beats by $0.04, revenue of $3.46M beats by $0.42MAugust 7, 2024 | msn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUAugust 3, 2024 | globenewswire.comShort Interest in Caribou Biosciences, Inc. (NASDAQ:CRBU) Increases By 13.6%Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 11,640,000 shares, a growth of 13.6% from the June 30th total of 10,250,000 shares. Based on an average daily volume of 2,550,000 shares, the days-to-cover ratio is currently 4.6 days. Currently, 14.6% of the shares of the stock are short sold.July 29, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJuly 26, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJuly 24, 2024 | prnewswire.comEvaluating Caribou Biosciences: Insights From 4 Financial AnalystsJuly 19, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJuly 10, 2024 | prnewswire.comCaribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory BoardJuly 9, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJuly 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJuly 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJune 30, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJune 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJune 22, 2024 | globenewswire.comShort Interest in Caribou Biosciences, Inc. (NASDAQ:CRBU) Grows By 9.7%Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) saw a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 11,510,000 shares, a growth of 9.7% from the May 15th total of 10,490,000 shares. Based on an average daily trading volume, of 2,210,000 shares, the short-interest ratio is presently 5.2 days. Currently, 14.4% of the company's shares are short sold.June 17, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUJune 13, 2024 | globenewswire.comCaribou Biosciences (NASDAQ:CRBU) Price Target Lowered to $9.00 at HC WainwrightHC Wainwright decreased their price objective on Caribou Biosciences from $24.00 to $9.00 and set a "buy" rating on the stock in a report on Tuesday.June 4, 2024 | marketbeat.comCaribou Biosciences (NASDAQ:CRBU) Downgraded by Evercore ISI to InlineEvercore ISI lowered Caribou Biosciences from an "outperform" rating to an "inline" rating and lowered their price target for the stock from $13.00 to $3.00 in a research report on Monday.June 3, 2024 | marketbeat.comCaribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024 | globenewswire.com Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. CRBU Media Mentions By Week CRBU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBU News Sentiment▼0.450.46▲Average Medical News Sentiment CRBU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBU Articles This Week▼62▲CRBU Articles Average Week Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SOPHiA GENETICS News Today Fate Therapeutics News Today Vaxart News Today Cellectis News Today Poseida Therapeutics News Today Atara Biotherapeutics News Today bluebird bio News Today Precision BioSciences News Today Kezar Life Sciences News Today Sangamo Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBU) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRBU Stock Alerts